Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
Information source: Watson Pharmaceuticals
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Overactive Bladder; Urinary Incontinence; Quality of Life
Intervention: oxybutynin transdermal delivery system (Oxytrol(r)) (Drug)
Phase: Phase 4
Sponsored by: Watson Pharmaceuticals
Official(s) and/or principal investigator(s):
Naomi V. Dahl, PharmD, Study Director, Affiliation: Watson Laboratories, Inc.
This study evaluates changes in health related quality of life outcomes in patients using
Official title: Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Change in health-related quality of life
Change in other outcomes such as:
effect of enhanced patient on any of the above outcomes
Minimum age: 18 Years.
Maximum age: N/A.
- Adult patients with one or more symptom of overactive bladder, including urge urinary
incontinence, urgency and/or frequency
- Patients for whom Oxytrol(r) is contraindicated.
- Patients treated with Oxytrol(r) prior to participation in this study.
- Patients residing in long-term care facilities or nursing homes.
Locations and Contacts
Mobile, Alabama, United States
Tucson, Arizona, United States
Torrance, California, United States
Rocky Hill, Connecticut, United States
Valdosta, Georgia, United States
Gretna, Louisiana, United States
Bloomfield Hills, Michigan, United States
Poughkeepsie, New York, United States
Winston-Salem, North Carolina, United States
Tomball, Texas, United States
Starting date: May 2004
Last updated: February 4, 2008